BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 1310509)

  • 1. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines.
    Kasahara K; Fujiwara Y; Sugimoto Y; Nishio K; Tamura T; Matsuda T; Saijo N
    J Natl Cancer Inst; 1992 Jan; 84(2):113-8. PubMed ID: 1310509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.
    Yamazaki K; Isobe H; Hanada T; Betsuyaku T; Hasegawa A; Hizawa N; Ogura S; Kawakami Y
    Cancer Chemother Pharmacol; 1997; 39(3):192-8. PubMed ID: 8996519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
    Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
    Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors.
    Binaschi M; Capranico G; De Isabella P; Mariani M; Supino R; Tinelli S; Zunino F
    Int J Cancer; 1990 Feb; 45(2):347-52. PubMed ID: 2154411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity.
    Jensen PB; Roed H; Sehested M; Demant EJ; Vindeløv L; Christensen IJ; Hansen HH
    Cancer Chemother Pharmacol; 1992; 31(1):46-52. PubMed ID: 1360876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.
    Oizumi S; Isobe H; Ogura S; Ishida T; Yamazaki K; Nishimura M; Kawakami Y; Dosaka-Akita H
    Anticancer Res; 2002; 22(6C):4029-37. PubMed ID: 12553028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
    Giaccone G; Gazdar AF; Beck H; Zunino F; Capranico G
    Cancer Res; 1992 Apr; 52(7):1666-74. PubMed ID: 1312895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response.
    Guinee DG; Holden JA; Benfield JR; Woodward ML; Przygodzki RM; Fishback NF; Koss MN; Travis WD
    Cancer; 1996 Aug; 78(4):729-35. PubMed ID: 8756364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
    de Jong S; Zijlstra JG; de Vries EG; Mulder NH
    Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
    Jensen PB; Christensen IJ; Sehested M; Hansen HH; Vindeløv L
    Br J Cancer; 1993 Feb; 67(2):311-20. PubMed ID: 8094293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
    van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
    Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.
    Kreisholt J; Sorensen M; Jensen PB; Nielsen BS; Andersen CB; Sehested M
    Br J Cancer; 1998 May; 77(9):1469-73. PubMed ID: 9652763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer.
    Shaw GL; Gazdar AF; Phelps R; Steinberg SM; Linnoila RI; Johnson BE; Oie HK; Russell EK; Ghosh BC; Pass HI; Minna JD; Mulshine JL; Ihde DC
    J Cell Biochem Suppl; 1996; 24():173-85. PubMed ID: 8806100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
    Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
    Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
    Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
    J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells.
    Takano H; Kohno K; Ono M; Uchida Y; Kuwano M
    Cancer Res; 1991 Aug; 51(15):3951-7. PubMed ID: 1649696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
    Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
    Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells.
    Montaudon D; Pourquier P; Denois F; de Tinguy-Moreaud E; Lagarde P; Robert J
    Eur J Biochem; 1997 Apr; 245(2):307-15. PubMed ID: 9151958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.